Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine

Advanced Prostate Cancer Consensus Conference (APCCC 2021)

Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

NANETS (North American Neuroendocrine Tumor Society) Symposium

34th Annual Congress of the European Association of Nuclear Medicine (EANM)

ESMO (European Society for Medical Oncology) Congress

Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting